To amend title XXVII of the Public Health Service Act to ensure the equitable treatment of covered entities and pharmacies participating in the 340B drug discount program, and for other purposes.
Key claim: A House bill would change federal health law so hospitals, clinics, and pharmacies in the 340B drug-discount program are treated more evenly, but it has only been sent to committee and does not yet change the program.
Abstract
(HR10937 · 119th Congress) Latest action (2026-10-29): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
The 340B program is one of the main federal levers affecting how much safety-net hospitals and clinics pay for outpatient drugs, and disputes between manufacturers, covered entities, and contract pharmacies have driven years of litigation and HRSA guidance. A House bill proposing ‘equitable treatment’ of 340B participants signals continued congressional interest in codifying rules of the road, though at the introduction stage it changes nothing for patients or providers.